This CPB has been revised to state that canakinumab is considered experimental and investigational for the treatment of cardiovascular disorders (including Kawasaki disease, myocardial infarction, myocarditis, and pericarditis), and hyper-ferritinemic syndromes (including macrophage activation syndrome).